Uroporphyrinogen decarboxylase: Optimizing radiotherapy for head and neck cancer

Future Oncology

Volumn 7, Issue 5, 2011, Pages 595-597

  Ito, Emma ^a   Yip, Kenneth W ^a   Liu, Fei Fei ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

chemosensitizer; chemotherapy; head and neck cancer; heme; iron; molecularly targeted agents; oxidative stress; radiosensitizer; radiotherapy; uroporphyrinogen decarboxylase

Indexed keywords

CETUXIMAB; GADOLINIUM TEXAPHYRIN; TIRAPAZAMINE; UROPORPHYRINOGEN DECARBOXYLASE;

CANCER INHIBITION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; COMORBIDITY; DISEASE FREE SURVIVAL; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; IONIZING RADIATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXIDATIVE STRESS; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW;

ANTIBODIES, MONOCLONAL; HEAD AND NECK NEOPLASMS; HUMANS; PORPHYRINS; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; TRIAZINES; UROPORPHYRINOGEN DECARBOXYLASE;

EID: 79956148112     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.27     Document Type: Review

References (18)

1. Lee N, Puri DR, Blanco AI, Chao KS: Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 29(4), 387-400 (2007). (Pubitemid 46623504)
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005). (Pubitemid 40372904)
3. Pai SI, Westra WH: Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu. Rev. Pathol. 4, 49-70 (2009).
4. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB: Head and neck cancer: past, present and future. Expert Rev. Anticancer Ther. 6(7), 1111-1118 (2006). (Pubitemid 44203388)
5. Bourhis J, Overgaard J, Audry H, et al.: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368(9538), 843-854 (2006). (Pubitemid 44292807)
6. Pignon JP, le Maitre A, Maillard E, Bourhis J: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92(1), 4-14 (2009).
7. Katz D, Ito E, Liu FF: On the path to seeking novel radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 988-996 (2009).
8. Brown JM: SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67(6), 1163-1170 (1993). (Pubitemid 23172847)
9. Reddy SB, Williamson SK: Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin. Investig. Drugs 18(1), 77-87 (2009).
10. Rischin D, Peters LJ, OSullivan B, et al.: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a Phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 28(18), 2989-2995 (2010).
11. Magda D, Miller RA: Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin. Cancer Biol. 16(6), 466-476 (2006). (Pubitemid 44780135)
12. Mehta MP, Shapiro WR, Phan SC, et al.: Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a Phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 1069-1076 (2009).
13. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006). (Pubitemid 43209104)
14. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11(1), 21-28 (2010).
15. Ito E, Yue S, Moriyama EH, et al.: Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci. Transl. Med. 3(67), 67RA7 (2011).
16. Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP: A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc. Natl Acad. Sci. USA 104(12), 5079-5084 (2007). (Pubitemid 47186179)
17. Whitby FG, Phillips JD, Kushner JP, Hill CP: Crystal structure of human uroporphyrinogen decarboxylase. EMBO J. 17(9), 2463-2471 (1998). (Pubitemid 28221182)
18. Lambrecht RW, Thapar M, Bonkovsky HL: Genetic aspects of porphyria cutanea tarda. Semin. Liver Dis. 27(1), 99-108 (2007).